Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

December 01, 2015 1:33 PM ET

Health Care Technology

Company Overview of Definiens AG

Company Overview

Definiens AG provides biomedical image analysis and data mining software solutions for life sciences, tissue diagnostics, and clinical digital pathology markets. It offers Definiens Tissue Studio, a solution for biomarker and morphological profiling in research and drug discovery on tissue samples, as well as detects regions of interest and distinguishes cell types and cell subtypes within target regions across various tissue slides; and Definiens Developer XD, a solution for scientists and image analysis experts to create and validate automated solutions for a range of biomedical image analysis problems. The company also provides Definiens Image Miner, a solution that integrates data mining...

Bernhard-Wicki-Straße 5

Munich,  80339


Founded in 1994


49 89 2311800


49 89 23118090

Key Executives for Definiens AG

Chief Executive Officer
Founder, Chief Technology Officer and Director
Chief Financial Officer
Chief Operating Officer
Compensation as of Fiscal Year 2015.

Definiens AG Key Developments

Definiens Increases Global Presence with Opening of Boston Office

Definiens AG announced the opening of its second location in the U.S. as a result of the company's growth and expansion in North America. The office, based in Boston, MA, will be managed by Dr. Thomas Nifong, Executive Vice President, Predictive Tests and houses Definiens Tissue Phenomics service team, bioinformatics and customer support for North America. The Boston office will be the primary location for Definiens project managers and services team to execute upon biomarker and companion diagnostic development projects in North America, expanding the company's capacity outside of the Munich headquarters. In addition to the team it currently has in place, the new location will recruit Data Analysts, Biostatisticians, Consultants, and commercially focused employees to meet growing customer demand.

Definiens Releases Biomarker Datafication Services for Oncology Clinical Development

Definiens announced a new suite of Biomarker Datafication Services for oncology clinical development programs. This package of services enables pharmaceutical and biotech companies to gather comprehensive data from their tissue samples which can be used to make critical decisions on drug candidate advancements and assess the potential of companion diagnostics for patient stratification. The Biomarker Datafication Services support data gathering and analysis for researchers working on projects in Exploratory Screening, Pharmacokinetics/Pharmacodynamics, and Companion Diagnostic development. By providing high quality image analysis screening for fast and quantitative measurement, users can receive powerful data output including biomarker expression profiles, biological response to therapy and continuous biomarker readouts, allowing highly advanced decision making and data analysis.

Definiens AG Secures EUR 15 Million Financing for Tissue Phenomics-Based Cancer Diagnostics; Appoints Rainer Strohmenger to the Board of Directors

Definiens AG announced that it has closed a round of financing for EUR 15 million. The round was led by Wellington Partners, a leading pan-European venture capital firm. Gilde Healthcare co-led the financing round and was joined by other existing investors Cipio Partners and TVM Capital in the financing. The new funds will allow Definiens to grow its global business in digital pathology image analysis and expand into digital tissue diagnostics. Major investments will be made in executing the company's Tissue Phenomics strategy, enabling partnerships with leading medical centers and pharmaceutical companies to advance the diagnosis and treatment of cancer. In conjunction with the financing, Dr. Rainer Strohmenger, General Partner and Managing Director for Wellington, will join Definiens' Board of Directors.

Similar Private Companies By Industry

Company Name Region
OntoChem Gmbh Europe
medigration Gesellschaft für medizinische Datenverarbeitung und Integration mbH Europe
GHX Europe GmbH Europe
Nexus/Holl GmbH Europe
Waldbrenner AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Definiens AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at